ProCE Banner Activity

IMROZ: Phase III Study of Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone vs Bortezomib, Lenalidomide, and Dexamethasone for Transplant-Ineligible, Newly Diagnosed MM

Conference Coverage
Slideset

Interim analysis of the phase III IMROZ study found that isatuximab plus VRd led to a significant improvement in median PFS vs VRd alone in patients with transplant-ineligible, newly diagnosed multiple myeloma.

Released: June 06, 2024

Expiration: June 05, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from GSK, Lilly, Novartis Pharmaceuticals Corporation, and Sanofi.

GSK

Lilly

Novartis Pharmaceuticals Corporation

Sanofi